



# DUKE

**DOCUMENT NUMBER:**

**DOCUMENT TITLE:**

**DOCUMENT NOTES:**

## Document Information

**Revision:**

**Vault:**

**Status:**

**Document Type:**

## Date Information

**Creation Date:**

**Release Date:**

**Effective Date:**

**Expiration Date:**

## Control Information

**Author:**

**Owner:**

**Previous Number:**

**Change Number:**

**Protocol Number:**

**Validation Protocol Title:**

Prepared By:  _____	Date:  _____
Approved By: Department Supervisor/Manager  _____	Date:  _____
Approved By: Medical Director  _____	Date:  _____
Approved By: Quality Systems Unit  _____	Date:  _____

*This form is to be used as a guide in the development of an analytical validation.  
Applicable contents can be imported into an MS Word document to create the validation  
protocol and final report.*

## **1. Table of Contents**

1.	Table of Contents .....	2
2.	Objective and Scope .....	3
2.1.	Validation Execution Prerequisites .....	3
3.	Introduction and Background.....	4
4.	List of Equipment and Reagents .....	6
5.	Accuracy .....	7
5.1.	Sample Preparation .....	7
5.2.	Acceptance Criteria .....	7
5.3.	Analysis Methodology .....	7
6.	Precision.....	8
6.1.	Repeatability .....	8
6.1.1.	Sample Preparation .....	8
6.1.2.	Acceptance Criteria .....	8
6.1.3.	Analysis Methodology .....	8
6.2.	Intermediate Precision.....	9
6.2.1.	Sample Preparation .....	9
6.2.2.	Acceptance Criteria .....	9
6.2.3.	Analysis Methodology .....	9
7.	Specificity .....	11
7.1.	Sample Preparation .....	11
7.2.	Acceptance Criteria .....	11
7.3.	Analysis Methodology .....	12
8.	Limit of Quantitation .....	13
8.1.	Sample Preparation .....	13
8.2.	Acceptance Criteria .....	13
8.3.	Analysis Methodology .....	14
9.	Linearity.....	15
9.1.	Sample Preparation .....	15
9.2.	Acceptance Criteria .....	15
9.3.	Analysis Methodology .....	16
10.	Range .....	17
10.1.	Sample Preparation.....	17
10.2.	Acceptance Criteria .....	17
10.3.	Analysis Methodology.....	17
11.	Amendment Revision History (as applicable) .....	18
12.	Final Report.....	18
12.1.	Non-Conformances .....	18
12.2.	Post-Execution Requirements .....	18

## **2. Objective and Scope**

*Clearly state the objective of the validation to validate a particular analytical method. List names/numbers of relevant SOPs to be followed during this validation. Insert information about scope, such as how many samples will be used or how many runs will be included, etc.*

*Example:*

*This protocol will define the samples, tests, and specifications used to monitor the stability of the hematopoietic progenitor cells, cord blood (HPC, Cord Blood) products manufactured by the Carolinas Cord Blood Bank (CCBB) under license by the FDA (DUCORD). The samples and data used in this protocol will be obtained from pre-cryopreservation data collected at the time of initial manufacturing and storage under liquid nitrogen compared to the data obtained upon thawing the cord blood unit specifically for the study. To ensure that the analytical data are consistent before and after cryopreservation, units included in the stability assessment will be selected via randomization from CCBB inventory and then thawed/tested by the Duke Stem Cell Laboratory (STCL). The specific data used to assess stability will be reported as described below.*

### **2.1. Validation Execution Prerequisites**

*Detail any pre-execution requirements for the validation protocol. This may include verification of qualification status of any equipment/systems required in the execution of protocol, any change controls necessary.*

### 3. Introduction and Background

*Provide details of the analytical method being validated, what it is used to assess, and principle for use. Validation parameters should meet the requirements of ICH Guideline Q2 (R1) and Guidance for Industry: Analytical Procedures and Methods Validation for Drugs and Biologics (July 2015).*

<i>Type of Analytical Procedure</i> <i>Characteristics</i>	<i>IDENTIFICATION</i>	<i>TESTING FOR IMPURITIES</i>  <i>Quantitation limit</i>	<i>ASSAY</i>  <i>- dissolution (measurement only)</i>  <i>- content / potency</i>
<i>Accuracy</i>	-	+      -	+
<i>Precision</i>	-	+      -	+
<i>Repeatability</i>	-	+ (1)    -	+ (1)
<i>Interm. Precision</i>	-		
<i>Specificity (2)</i>	+	+      +	+
<i>Detection Limit</i>	-	- (3)    +	-
<i>Quantitation Limit</i>	-		
<i>Linearity</i>	-	+      -	-
<i>Range</i>	-	+      -	+
	-	+      -	+

*Key:*

- signifies that this characteristic is not normally evaluated
- + signifies that this characteristic is normally evaluated
- (1) in cases where reproducibility has been performed, intermediate precision is not needed
- (2) lack of specificity of one analytical procedure could be compensated by other supporting analytical procedure(s)
- (3) may be needed in some cases

*Example:*

*This validation protocol was generated in accordance with ICH Guideline Q2 (R1), Validation of Analytical Procedures and SOP COMM-QA-044, Approaches to Validation. The following analytical performance parameters will be assessed:*

1. Accuracy
2. Precision
  - a. Repeatability
  - b. Intermediate Precision
3. Specificity
4. Limit of Quantitation
5. Linearity
6. Range

*Details regarding each of these parameters and how they will be assayed, the equipment used, reagents, and how samples are prepared are provided in the sections below.*

*When switching to a new analytical method, a comparability study should be considered to verify that the new method performs comparably or better than the previously validated method. Every effort should be made to ensure that any outside sources of variation between methods are minimized. When making changes to a validated method, an assessment should be made to determine if re-validation is needed. This may include comparability of one or more parameters, as applicable.*

*Procedures will be performed per the following SOPs.*

**Table 3.1**

SOP Number	SOP Title

*Following execution of this protocol, a final report will be generated, including data and final conclusions. Data must be available to establish that the analytical procedures used in testing meet proper standards of accuracy, sensitivity, specificity, and reproducibility (as applicable) and are suitable for their intended purpose.*

#### 4. List of Equipment and Reagents

*List and describe equipment and reagents to be used in the analytical validation. Equipment should be appropriately qualified prior to use in the validation.*

*Example:*

*The following equipment and reagents will be used during execution of this validation protocol. This equipment is used when performing this XXX procedure during standard practice in the XXX Laboratory. The validation will be performed with appropriately sized, calibrated pipettes.*

**Table 4.1**

<b>Equipment/Reagent</b>	<b>Serial Number/Label</b>	<b>Location</b>

## **5. Accuracy**

*Accuracy is defined as the closeness of agreement between the value which is accepted either as a conventional true value or an accepted reference value and the value found.*

### **5.1. Sample Preparation**

*Describe sample preparation.*

*Example:*

*Spiked samples will be prepared at three concentrations over the range of 50 to 150% of the target concentration. Three individually prepared replicates at each concentration will be analyzed. When it is impossible or difficult to prepare known placebos, a low concentration of a known standard will be used.*

### **5.2. Acceptance Criteria**

*Describe acceptance criteria. This is typically reported as CV, % change, or % difference.*

*Example:*

*The mean recovery must be within 90 to 110% of the theoretical value.*

### **5.3. Analysis Methodology**

*List and describe statistical analyses here.*

*Example:*

*For each sample, the theoretical value and the assay value will be reported. The mean, standard deviation, and percent recovery will be calculated for all samples.*



## 6. Precision

### 6.1. Repeatability

*Repeatability is defined as the precision under the same operating conditions over a short interval of time. Repeatability will be demonstrated by a single operator.*

#### 6.1.1. Sample Preparation

*Describe sample preparation.*

#### 6.1.2. Acceptance Criteria

*Provide details of the acceptance criteria. Refer to ICH guidance to define acceptance criteria.*

*Example:*

*The acceptance criteria for repeatability are XXX.*

#### 6.1.3. Analysis Methodology

*List and describe statistical analyses here.*

*Example:*

*Variability will be assessed by comparing triplicate results at each sample concentration. The standard deviation, relative standard deviation (coefficient of variation), and confidence interval will be reported.*

**Table 6.1**

<i>Test Sample</i>	<i>Results % viability</i>	<i>Standard deviation, relative standard deviation or coefficient of variation, and confidence interval</i>	<i>Specification</i>
<i>High-1</i>			$\leq 5\% CV$
<i>High-2</i>			
<i>High-3</i>			
<i>Intermediate-1</i>			$\leq 5\% CV$
<i>Intermediate-2</i>			
<i>Intermediate-3</i>			
<i>Low-1</i>			$\leq 5\% CV$
<i>Low-2</i>			
<i>Low-3</i>			

## **6.2. Intermediate Precision**

*Intermediate precision is defined as the within-laboratory variations: different days, different analysts, different equipment, etc.*

*Provide details of intermediate precision.*

*Example:*

*Intermediate precision will be measured by 3 operators, each testing 2 samples (high and low viability) on the same day, using two hemocytometers and two different lots of trypan blue. Only one microscope is currently used in the CCBB Processing Laboratory for this trypan blue assay. Thus, only one instrument will be tested. Each of the high and low viability samples will be tested in triplicate (providing a total of 9 values for each sample).*

*It was decided to have 3 operators test intermediate precision on the same day in order to allow for the use of a single, fresh, processed cord blood test sample.*

### **6.2.1. Sample Preparation**

*Describe sample preparation.*

*Example:*

*The first test sample, high viability, will consist of fresh processed cord blood alone. The low viability test sample will consist of fresh processed cord blood diluted 1:10 with the 1% DMSO frozen/thawed, processed cord blood. Specifically, 10  $\mu$ L of fresh, processed cord blood will be mixed with 90  $\mu$ L of the thawed 1% DMSO sample, yielding a sample with low viability.*

*Operator 1 will first create each of the high and low viability samples based on the instructions above. Samples will be processed according to the SOP and then tested in triplicate. Operator 2 will prepare and test the same two samples, using a different hemocytometer from operator 1 and a different lot of trypan blue. Operator 3 will prepare and test the same two samples, randomly choosing the hemocytometer and the lot of trypan blue.*

### **6.2.2. Acceptance Criteria**

*Describe acceptance criteria.*

*Example:*

*The target value for intermediate precision is  $\leq 10\%$  variability for the same sample between different operators/days.*

### **6.2.3. Analysis Methodology**

*List and describe statistical analyses here.*

*Variability will be assessed by comparing all results at each sample concentration. The standard deviation, relative standard deviation (coefficient of variation), and confidence interval will be reported.*

**Table 6.2**

<i>Test Sample</i>	<i>Operator #1 % Viability</i>	<i>Operator #2 % Viability</i>	<i>Operator #3 % Viability</i>	<i>Standard deviation, relative standard deviation or coefficient of variation, and confidence interval</i>	<i>Specification</i>
<i>High-1</i>					$\leq 10\% CV$
<i>High-2</i>					$\leq 10\% CV$
<i>High-3</i>					$\leq 10\% CV$
<i>Low-1</i>					$\leq 10\% CV$
<i>Low-2</i>					$\leq 10\% CV$
<i>Low-3</i>					$\leq 10\% CV$

## **7. Specificity**

*Specificity is defined as the ability to assess unequivocally the analyte in the presence of components which may be expected to be present. Specificity will be demonstrated by a single operator.*

### **7.1. Sample Preparation**

*Provide details of the sample preparation.*

*Example:*

*Two possible components in cord blood that could impact the assessment of viability are high levels of dead cells or the presence of high levels of red blood cells. In the assessment of linearity (Section 9), viability will be measured over a range of approximately 10-100% viable cells, and thus specificity with respect to high levels of dead cells will be determined.*

*Processed cord blood typically has a hematocrit of 20-30%. For this assessment of specificity, processed cord blood (low red blood cells) will be diluted with red blood cells derived from the same cord blood unit at a ratio of 1:1 to create a sample with high red blood cells. Specifically, the hematocrit of the processed cord blood will be measured along with that of the isolated red blood cells. Fifty microliters of red blood cells will be added back to 50  $\mu$ L of the processed cord blood, and the expected hematocrit of the new solution will be documented. We expect this value to be around 60%.*

*Each sample will be prepared as defined in the SOP and tested in triplicate. Specificity will be determined by comparing the variability of viability between test conditions.*

### **7.2. Acceptance Criteria**

*Describe acceptance criteria.*

*Example:*

*The target value for specificity is  $\leq 5\%$  variability between test results.*

### 7.3. Analysis Methodology

List and describe statistical analyses here.

*Example:*

*Variability will be assessed by comparing triplicate results at each sample concentration. Specificity will be assessed by calculating variability between each test condition (high, intermediate, and low RBCs). The standard deviation, relative standard deviation (coefficient of variation), and confidence interval will be reported.*

**Table 7.1**

<i>Test Sample</i>	<i>Results % viability</i>	<i>Standard deviation, relative standard deviation or coefficient of variation, and confidence interval</i>	<i>Specification</i>
<i>High-1</i>			$\leq 5\% CV$
<i>High-2</i>			
<i>High-3</i>			
<i>Low-1</i>			$\leq 5\% CV$
<i>Low-2</i>			
<i>Low-3</i>			

## **8. Limit of Quantitation**

*Quantitation limit is defined as the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. Limit of quantitation will be demonstrated by a single operator.*

*Provide details of the quantitation limit.*

*Example:*

*Based on the current SOP, a visual evaluation is performed to quantitate the results of this assay. A technician must count at least 100 cells. If the number of cells is not sufficient in four large squares of one chamber, both chambers of the hemocytometer must be inoculated. Then, all 8 sides must be counted before performing viability calculations.*

### **8.1. Sample Preparation**

*Describe sample preparation.*

*Example:*

*Three different fresh processed cord blood samples will be independently prepared according to the SOP and diluted to give approximately 100 cells in the 8 squares to be counted per the SOP. Each sample will be tested in triplicate. This will be done on a single instrument.*

### **8.2. Acceptance Criteria**

*Describe acceptance criteria.*

*Example:*

*The precision between the replicates of each sample must achieve a target value of  $\leq 5\%$ .*

### 8.3. Analysis Methodology

*List and describe statistical analyses here.*

*Example:*

*Precision will be calculated as indicated above. Variability will be assessed by comparing duplicate results for each sample. The standard deviation, relative standard deviation (coefficient of variation), and confidence interval will be reported.*

**Table 8.1**

<b><i>Test Sample</i></b>	<b><i>Results (% viability)</i></b>	<b><i>Standard deviation, relative standard deviation or coefficient of variation</i></b>	<b><i>Specification</i></b>
<i>A-1</i>			$\leq 5\% CV$
<i>A-2</i>			
<i>A-3</i>			
<i>B-1</i>			$\leq 5\% CV$
<i>B-2</i>			
<i>B-3</i>			
<i>C-1</i>			$\leq 5\% CV$
<i>C-2</i>			
<i>C-3</i>			

## **9. Linearity**

*The linearity of an analytical procedure is its ability (within a given range) to obtain test results which are directly proportional to the concentration (amount) of analyte in the sample. Linearity will be tested by a single operator.*

### **9.1. Sample Preparation**

*Provide details of the sample preparation.*

*Example:*

*The trypan blue assay is used to measure dead cells as a component of live and dead cells to calculate viability. To test linearity, a sample of post-processed cord blood will be frozen in 1% DMSO to -150°C and thawed to room temperature to create a sample of increased dead cells. This sample with low cell viability will be mixed with a fresh sample in the ratios listed in the table below to create a range of 5 different sample concentrations. These samples will then be prepared according to the SOP and tested in triplicate. This will be done on a single instrument.*

### **9.2. Acceptance Criteria**

*Describe acceptance criteria.*

*Example:*

*Acceptable linearity is the measurement of non-viable cells in increasing numbers of viable cells (from A to E in the table below). Furthermore, the viability variability of each sample should be within a target value of 5% of the estimated viability based on the initial readings of the fresh and frozen samples.*



### 9.3. Analysis Methodology

List and describe statistical analyses here.

Example:

The viability percentages from the linearity assessment will be plotted. A regression line will be calculated, and the correlation coefficient, y-intercept, slope of the regression line, and residual sum of the squares will be submitted.

**Table 9.1**

<b>Test Sample</b>	<b><i>Fresh sample mixed with frozen/thawed sample (with 1% DMSO) Fresh/frozen thawed</i></b>	<b><i>Specification</i></b>	<b><i>Results % Viability</i></b>	<b><i>% Recovery</i></b>
<i>A-1</i>	<i>100% fresh/0% frozen-thawed</i>	<i>&gt;90%</i>		
<i>A-2</i>				
<i>A-3</i>				
<i>B-1</i>	<i>75% fresh/25% frozen-thawed</i>	<i>75%</i>		
<i>B-2</i>				
<i>B-3</i>				
<i>C-1</i>	<i>50% fresh/50% frozen-thawed</i>	<i>45%</i>		
<i>C-2</i>				
<i>C-3</i>				
<i>D-1</i>	<i>25% fresh/75% frozen-thawed</i>	<i>25%</i>		
<i>D-2</i>				
<i>D-3</i>				
<i>E-1</i>	<i>0% fresh/100% frozen-thawed</i>	<i>5%</i>		
<i>E-2</i>				
<i>E-3</i>				

## **10. Range**

*Range is defined as the interval between the upper and lower concentration (amounts) of analyte in the sample (including those concentrations) for which it has been demonstrated that the analytical procedure has a suitable level of precision, accuracy, and linearity.*

*Provide details of the analyte range.*

*Example:*

*Based on the current SOP, a visual evaluation is performed to quantitate the results of this assay. A technician must count at least 100 cells. If the number of cells is not sufficient in four large squares of one chamber, both chambers of the hemocytometer must be inoculated. Then, all 8 sides must be counted before performing viability calculations. Thus, because a technician must count at least 100 cells in order for the assay result to be valid, a formal range for this assay has not been established.*

*Furthermore, if cells are overlapping or too dense to distinguish between viable and non-viable cells, a greater dilution is prepared, and counting then proceeds using the standard protocol. This upper limit has not been defined but is left to the analyst's discretion.*

### **10.1. Sample Preparation**

*Describe sample preparation.*

*Example:*

*The linearity assessment in Section 9 should help demonstrate that the trypan blue assay can make viability determinations over a wide range of values.*

### **10.2. Acceptance Criteria**

*Describe acceptance criteria.*

*Example:*

*Not applicable since range will not be determined.*

### **10.3. Analysis Methodology**

*List and describe statistical analyses here.*

*Example:*

*Not applicable since range will not be determined.*

## **11. Amendment Revision History (as applicable)**

*Provide a brief description of the change(s) from the previous review and approval. Include justification for the change(s).*

## **12. Final Report**

*A final report will be generated after execution of this protocol and provided to the Medical Director and QSU for review. The final report will include completed tables with data and other information as described in this protocol. In addition, summaries, conclusions, and recommendations will be included.*

### **12.1. Non-Conformances**

*Describe any protocol generation errors, non-conformances, or deviations that occurred during execution of the protocol. Minimally, this will also include an assessment/justification of any perceived impact to the validation. If no instances of non-conformance are noted, thus deviations are not required, this rationale should be stated within the summary report.*

*If, during the execution of a validation protocol, there is a deviation from an existing, effective version of an SOP in MasterControl, a formal deviation and investigation report, per COMM-QA-042 Deviations and Investigations, will be launched and referenced. All events associated with the execution of a validation protocol must be closed before signoff of the associated validation summary report.*

*NOTE: If a deviation is launched within MasterControl, this number must be referenced in the validation summary report. See COMM-QA-044 Approaches to Validation for clarification on requirements for situations when a MasterControl event is required.*

### **12.2. Post-Execution Requirements**

*Following execution of the validation protocol, describe in the report if any change control requests are necessary as a result of this validation in order to ensure the validated parameters/processes are incorporated into applicable SOPs/batch records. If change controls are not determined to be necessary, this rationale should be stated within the summary report.*

*NOTE: If a change control request is launched within MasterControl, this number must be referenced in the validation summary report.*

## Signature Manifest

**Document Number:** COMM-QA-044 FRM2

**Revision:** 05

**Title:** Analytical Validation Protocol FRM2

**Effective Date:** 08 Jun 2020

All dates and times are in Eastern Time.

### COMM-QA-044 FRM2 Analytical Validation Protocol

#### Author

Name/Signature	Title	Date	Meaning/Reason
Patrick Killela (PK37)		21 May 2020, 09:00:24 PM	Approved

#### Medical Director

Name/Signature	Title	Date	Meaning/Reason
Joanne Kurtzberg (KURTZ001)		22 May 2020, 10:35:49 AM	Approved

#### Quality

Name/Signature	Title	Date	Meaning/Reason
Bing Shen (BS76)		22 May 2020, 11:18:56 AM	Approved

#### Document Release

Name/Signature	Title	Date	Meaning/Reason
Sandy Mulligan (MULLI026)		28 May 2020, 09:07:50 PM	Approved